Reinforcement Learning from eXperimental Feedback (RLXF) used a learned fluorescence reward model to align ESM-2 with measured CreiLOV sequence-function data. In the peer-reviewed study, the authors expressed 60 generated variants in E. coli and measured cellular fluorescence; six of ten aligned ESM-2 five-mutant designs exceeded CreiLOV fluorescence, and three aligned designs exceeded CreiLOV-T7S. The first bioRxiv version (posted 2025-05-08) already described experimentally enhanced fluorescence from RLXF-aligned designs; detailed measurements here are from the 2026 journal version. The earlier ICLR workshop comparison was computational and did not report new wet-lab fluorescence assays.
Technology: 650-million-parameter ESM-2 protein language model aligned by reinforcement learning from experimental feedback using a learned sequence-fluorescence reward model
Family ESM / ESMFold: profile · models page
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The journal article reports 60 CreiLOV designs expressed in E. coli BL21(DE3) and measured for total cellular fluorescence. Six of ten aligned ESM-2 five-mutant designs exceeded CreiLOV fluorescence, and three aligned designs exceeded the prior CreiLOV-T7S control; the brightest reported design was 1.2-fold above T7S.
- Still unknown: The measurements use total cellular fluorescence and are specific to tested designs/conditions; broader cellular contexts, protein function beyond fluorescence, and independent reproduction are not established. The qualitative enhanced-fluorescence result is present in the 2025 preprint abstract; detailed design-set metrics are verified from the later journal version.
- AI role: A learned sequence-fluorescence reward model trained on measured CreiLOV variant data guides supervised fine-tuning and PPO alignment of ESM-2. The aligned model generates the candidate sequences that were expressed and assayed.
Evidence sources: https://www.biorxiv.org/content/10.1101/2025.05.02.651993v1 · https://www.nature.com/articles/s41467-026-77557-2 · https://openreview.net/pdf?id=yuiQMh52Bm
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv v1 abstract, posting-date and affiliation metadata; primary GEM@ICLR workshop paper full text for methods and experimental outcomes; primary Nature Communications indexed text for later journal-version comparison..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An uncertainty-aware Gaussian process regression workflow iteratively selected 23 synthetic α/β-peptide analogues for synthesis and measurements of fungal inhibition and human-red-blood-cell hemolysis. One lead, peptide 6-4, was a measured variant of an existing aurein-derived template and achieved a selectivity index of 57.1 (60.9 using the study’s finer MIC interval) versus 1.2 for aurein 1.2. Its high selectivity was driven by low hemolysis; the result is a specific peptide-design and assay contribution, not a new peptide scaffold or evidence of therapeutic efficacy. The ChemRxiv v1 result was posted on 2024-10-04; the peer-reviewed journal article followed in 2025.
Technology: Iterative uncertainty-aware Gaussian process regression using molecular descriptors and measured antifungal/hemolysis labels
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Across six iterative rounds, uncertainty-aware Gaussian process regression selected 23 peptide variants for synthesis and antifungal/hemolysis assays. Lead 6-4 had a selectivity index of 57.1 (60.9 using the study’s finer MIC interval), versus 1.2 for aurein 1.2; the authors attribute the selectivity to reduced hemolysis.
- Still unknown: Peptide 6-4 modifies a known aurein-derived template. The result is a measured sequence and assay outcome, not evidence of a new scaffold or therapeutic efficacy. The version-specific first public result is the 2024 ChemRxiv preprint; the journal article followed in 2025.
- AI role: An uncertainty-aware Gaussian process regression model selected peptide variants for synthesis and assays, and measured outcomes were fed back into subsequent selection rounds.
Evidence sources: https://chemrxiv.org/engage/chemrxiv/article-details/67a7e4386dde43c9081bdfc1 · https://pubs.rsc.org/en/content/articlepdf/2025/sc/d4sc06689h · https://pubmed.ncbi.nlm.nih.gov/40028619/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary ChemRxiv version-history record and v2 manuscript; primary RSC indexed full article PDF, including sequence tables, Results, Methods and publication metadata; PubMed primary abstract/affiliation metadata..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Mutational Effect Transfer Learning (METL) combines transformer pretraining on simulated protein biophysics with fine-tuning on experimental sequence–function data. Using only 64 experimental GFP examples, the authors designed 20 previously untested variants and measured their fluorescence; 16 showed measurable fluorescence, although none was brighter than wild-type GFP. The result demonstrates functional design under a small-data setup, not improved brightness over wild type. The result was present in the bioRxiv version posted 2024-03-17; the GEM@ICLR 2024 workshop paper provides the detailed 20-variant assay report, and the later journal version is the same study.
Technology: Mutational Effect Transfer Learning (METL), a transformer protein language model pretrained on simulated biophysical features and fine-tuned on experimental data
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Twenty METL-designed GFP variants were synthesized and experimentally measured; 16 showed measurable fluorescence, but none exceeded wild-type brightness.
- Still unknown: The panel contains 20 designed variants in a specific GFP task; the result does not show improvement over wild-type brightness or establish general performance across protein families.
- AI role: METL-Local was pretrained on simulated GFP sequence/biophysical data, fine-tuned using 64 experimental examples, and used with sequence optimization to select variants for wet-lab testing.
Evidence sources: https://www.biorxiv.org/content/10.1101/2024.03.15.585128v1 · https://openreview.net/pdf?id=hWISqnHBr7
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv v1 indexed abstract, posting date and affiliation metadata; primary GEM@ICLR workshop paper full text with methods and experimental outcomes..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning-guided iterative design–test–learn workflow engineered fatty acyl-ACP reductase variants for microbial fatty alcohol production. Across ten rounds, the study reports over twice the production of the starting natural sequences under tested conditions; the top sequence also had enhanced catalytic rate on palmitoyl-ACP. These are laboratory results, not industrial-scale production. The journal article date is used here; the earlier preprint’s exact posting and result-version differences were not checked.
Technology: Machine-learning-guided protein engineering; Gaussian-process optimization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The paper reports ten design–test–learn rounds, in-vivo microbial fatty-alcohol production and catalytic-rate characterization on palmitoyl-ACP.
- Still unknown: Results are under the study’s microbial test conditions and do not establish industrial production; exact preprint-version results remain unchecked.
- AI role: Machine-learning models iteratively selected reductase sequences for experimental testing and subsequent model updates.
Evidence sources: https://www.nature.com/articles/s41467-021-25831-w
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary Nature Communications indexed full text, abstract, article date, author affiliations; preprint chronology not fully checked..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.